Xlife Sciences AG's gross profit for the
six
months ended in Dec. 2025 was CHF-0.18 Mil. Xlife Sciences AG's gross profit for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.01 Mil.
Xlife Sciences AG had a gross margin of 224.05% for the quarter that ended in Dec. 2025 => Durable competitive advantage
During the past 8 years, the highestGross Margin % of Xlife Sciences AG was 65.87%. The lowest was -6.55%. And the median was 34.76%.
Xlife Sciences AG (XSWX:XLS) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Xlife Sciences AG had a gross margin of 224.05% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Xlife Sciences AG Gross Profit Related Terms
Xlife Sciences AG Gross Profit Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, ALNY: Gross Profit Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Gross Profit distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.01 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Xlife Sciences AG (XSWX:XLS) has a Gross Profit of CHF0.01 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Gross Profit too high?
Xlife Sciences AG's current Gross Profit is CHF0.01 Mil. Overall, Xlife Sciences AG has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Gross Profit compare to VRTX and REGN?
Xlife Sciences AG's Gross Profit of CHF0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Gross Profit is CHF0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.24, compared to a current price of CHF18.60 — trading 156.9% above its estimated fair value. The current Gross Profit is CHF0.01 Mil. Xlife Sciences AG's overall GF Score™ is 52/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Gross Profit is CHF0.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF18.60 is trading 156.9% above its estimated GF Value™ of CHF7.24.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Gross Profit: CHF0.01 Mil
GF Value™: CHF7.24 vs. price of CHF18.60 (156.9% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
52GF Score
Get the complete analysis for XSWX:XLS
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
